Hot Features
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which completed Phase II clinical trial for the treatment of peripheral arterial disease, chronic limb t... Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which completed Phase II clinical trial for the treatment of peripheral arterial disease, chronic limb threatening ischemia, cardiovascular ischemia and angina, and vascular dementia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0.055 | 0.055 | 0.055 | 6000 | 0.055 | CS |
| 4 | 0.005 | 10 | 0.05 | 0.055 | 0.05 | 6177 | 0.05315066 | CS |
| 12 | -0.015 | -21.4285714286 | 0.07 | 0.07 | 0.04 | 25611 | 0.05787107 | CS |
| 26 | -0.035 | -38.8888888889 | 0.09 | 0.11 | 0.04 | 44420 | 0.0793737 | CS |
| 52 | -0.09 | -62.0689655172 | 0.145 | 0.155 | 0.04 | 110655 | 0.09291105 | CS |
| 156 | -0.065 | -54.1666666667 | 0.12 | 0.425 | 0.035 | 142436 | 0.12883831 | CS |
| 260 | -0.23 | -80.701754386 | 0.285 | 0.425 | 0.035 | 114549 | 0.15295839 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.